Where the work stands. Where the opportunity begins.
Software needs evidence of how people can use it; a biological question needs an appropriate experiment; a material needs performance in its intended application. This page explains the current public portfolio stages so that prospective customers, collaborators and investors can choose a conversation that matches the work. Editorial review: 14 October 2026.
PHARMORIS and Medicines Intelligence
PHARMORIS is in controlled product development and evaluation planning. The Medicines Action Layer is its commercial proposition: connecting source-linked evidence, accountable human decisions, implementation and subsequent review. The wider Medicines Intelligence work explores decision problems across community pharmacy, primary care, health systems, pharmaceutical organisations and the supply chain. These use-case pages describe proposed value and evaluation questions, rather than independently launched products.
A useful discussion should establish the workflow, the available demonstration and the work required for a credible evaluation. That may begin with an authorised document comparison or a defined preparation task. It should also identify the existing alternative, professional review and support effort. Product availability, contractual scope and any implementation commitment need to be agreed for the specific engagement.
Regional feasibility and future applications
PHARMORIS-SCOT concerns Scottish Enterprise-supported feasibility work around prioritisation, dossier preparation and deployment modelling for NHS generic-medicines adoption. PHARMORIS-INDIA is a development pathway focused on selecting a locally relevant medicines use case and understanding its requirements. Programme support and a development direction should be read within their named scope, without inferring a customer deployment or an institution's adoption decision.
An opportunity in another setting must earn its own evidence. Different commissioning arrangements, data access, professional responsibilities and operating conditions can change what is useful. The relevant question is not whether an idea can be described globally, but whether a defined local task and accountable buyer justify further investigation. We welcome that specificity at the beginning of a regional conversation.
Biomedical research
The glioblastoma recurrence programme is in scientific design and development planning, including specialist discussions and patient-involvement planning. It is one aspect of a broader research direction. The public material explains biological questions and relevant published research while distinguishing external findings from work undertaken by NEUVIOR. Published figures retain their authorship, experimental context and source information.
NEUVIOR is not currently recruiting people to a glioblastoma clinical trial or offering an experimental treatment. Research collaboration can instead concern an appropriate question, methodology, expertise or future study design. Any proposed investigation would need its own responsibilities and approvals. A compelling scientific rationale is a starting point for development; it is not a treatment result or evidence that a therapy is available.
Resource Economics
ZYLON has completed its initial feasibility study. Further questions concern bio-derived material performance, resource recovery and a defined industrial application. PHARMORIS-ECO is an active feasibility programme investigating energy performance in fixed pharmaceutical manufacturing chilling and freezing. Both sit within Resource Economics, where scientific performance and the practical economics of industrial adoption have to be considered together.
An industrial conversation should identify the process boundary, the relevant baseline and the evidence needed to judge a change. Material performance, energy use, costs and operating constraints are distinct measures. A completed feasibility activity can support a more precise next experiment, but it does not establish a commercially qualified material, an installed industrial system or a result in a prospective customer's facility.
Constellation
Constellation is a location-neutral campus concept with Scotland under consideration for a possible first destination. Its ambition brings research space, enterprise, public discovery and a wider community of activity into one proposed environment. The concept and visual studies support discussion of the model; they do not establish an operating campus, land control, construction finance or installed scientific capability.
The next development questions concern demand, a suitable site, operating responsibilities, programme design and a credible investment case. The longer-term ambition for eight destinations by 2045 depends on each stage becoming justified. A potential participant can contribute by describing a real space or service need, a public-discovery opportunity or expertise relevant to assessing the proposal, without implying an agreement to occupy or fund it.
Match the next commitment to the evidence
NICE (2022), evidence standards framework and MHRA (2023), intended-purpose guidance are useful external references for thinking about evidence and intended use in digital-health development. They do not confer a NEUVIOR approval or status. Across the portfolio, the practical next step is to agree the question, current stage, necessary comparison and appropriate reviewers. Any availability, fee or delivery commitment belongs in that specific discussion.
